Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6618857 | 0.86 | MAPT (0.61) | HCAR3MAPTSMN1; SMN2HTTMEN1 | |
| SCHEMBL6622671 | 0.83 | POLB (0.47) | MAPTSMN1; SMN2MEN1KMT2APRSS1 | |
| SCHEMBL6620664 | 0.77 | HTT (0.60) | MAPTSMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL10383535 | 0.77 | SMN1; SMN2 (0.63) | MAPTSMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL11682628 | 0.77 | MEN1 (0.60) | MAPTSMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL3278681 | 0.76 | HCAR3 (0.78) | HCAR3MAPTPRSS1ALDH1A1 | |
| SCHEMBL7973678 | 0.76 | SMN1; SMN2 (0.62) | HCAR3MAPTSMN1; SMN2KMT2APRSS1 | |
| SCHEMBL6925445 | 0.76 | MEN1 (0.58) | MAPTSMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL4459876 | 0.72 | HCAR3 (0.50) | HCAR3MAPTSMN1; SMN2HTTKMT2A | |
| SCHEMBL27595536 | 0.71 | ALDH1A1 (0.49) | MAPTSMN1; SMN2HTTPRSS1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825219-B2 | NITROGEN COMPOUNDS SUCH AS 4-((5-(CYCLOHEXYL-METHYL-CARBAMOYL) -2(THIOPHENE-2-CARBONYL)-AMINO)BENZIMIDAZOL-1-YL)-BUTYRIC ACID ADMINISTERED FOR THE PROPHYLAXIS OF INFLAMMATORY, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030144281-A1 | Substituted benzimidazole compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144281-A1 | Substituted benzimidazole compounds | HRH2, HRH4, HRH1 | HCAR3 2279/4885MAPT 3987/4885SMN1; SMN2 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.